This is a multicenter, randomized, parallel controlled Phase IV clinical study to evaluate the safety and efficacy of amino acid (15) peritoneal dialysis solution in patients undergoing peritoneal dialysis with malnutrition in CAPD patients undergoing peritoneal dialysis maintenance.
18 to 75 years of age (including 18 and 75 years of age), regardless of sex;
Stable CAPD patients treated with peritoneal dialysis for greater than or equal to 3 months;
25 ≤ serum ALB ≤ 40 g/L on two consecutive occasions prior to enrollment (two occasions one week apart);
Blood potassium ≥ 3.5 mmol/L
Within the past 3 months prior to the screening period, there has been a history of peritonitis, other infections, or inflammatory diseases, with hospitalization records;
The possibility of receiving a kidney transplant during the study period;
Patients with inadequate dialysis and screening period kt/v<1.4;
Patients with hemoglobin less than 80g/L during the screening period;